Rhenman & Partners Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Rhenman & Partners Asset Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4M	Hold	15,000	–	–	0.38%	80
2026 Q1	$3.43M	Hold	15,000	–	–	0.42%	69
2025 Q4	$3.2M	Buy	+15,000	New	+$3.1M	0.3%	77

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Rhenman & Partners Asset Management's ASND Position: Q2 2026 in Review

Rhenman & Partners Asset Management held its Ascendis Pharma A/S (ASND) position steady in Q2 2026 at 15,000 shares worth $4M. The position accounts for 0.38% of the portfolio, ranked #80.

Rhenman & Partners Asset Management first reported a position in ASND in Q4 2025 and has held it in 3 quarters since. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Rhenman & Partners Asset Management held 15,000 shares of Ascendis Pharma A/S worth $4M as of Q2 2026.
Rhenman & Partners Asset Management left its Ascendis Pharma A/S share count unchanged in Q2 2026.
Ascendis Pharma A/S made up 0.38% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #80 holding.
Rhenman & Partners Asset Management first reported a position in Ascendis Pharma A/S in Q4 2025 and has held it in 3 quarters since.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.